IDH1 and central nervous system neoplasm: Because our model’s misclassified IDH-wildtype patients were associated with the absence of + 7/ − 10 and younger age, attributes of pediatric-type tumors, we tested whether the status cIMPACT-NOW update 3 [8] molecular markers (which are incorporated in the upcoming WHO CNS tumor classification fifth edition [40]) explained the improved survival of misclassified histological WHO grade 4 IDH-wildtype tumors.